KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Short term Debt (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Short term Debt data on record, last reported at $3.6 billion in Q1 2025.

  • For Q1 2025, Short term Debt rose 45.19% year-over-year to $3.6 billion; the TTM value through Mar 2025 reached $3.6 billion, up 45.19%, while the annual FY2025 figure was $3.6 billion, 41.51% up from the prior year.
  • Short term Debt reached $3.6 billion in Q1 2025 per TAK's latest filing, up from $2.5 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $3.6 billion in Q1 2025 and bottomed at $1.7 billion in Q1 2022.
  • Average Short term Debt over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2024.
  • Peak YoY movement for Short term Debt: skyrocketed 166.61% in 2021, then fell 28.01% in 2022.
  • A 5-year view of Short term Debt shows it stood at $2.3 billion in 2021, then fell by 28.01% to $1.7 billion in 2022, then soared by 52.17% to $2.6 billion in 2023, then decreased by 3.48% to $2.5 billion in 2024, then skyrocketed by 45.19% to $3.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $3.6 billion in Q1 2025, $2.5 billion in Q1 2024, and $2.6 billion in Q1 2023.